A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-22Actual
Enrollment · participants617Actual
Source updated2026-02-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.